Tyra Biosciences (TYRA) Equity Average (2020 - 2026)

Tyra Biosciences has reported Equity Average for 7 years, with the latest figure at $323.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 2.99% year-over-year to $323.4 million; the trailing twelve-month figure through Mar 2026 stood at $323.4 million (down 2.99% YoY), and the FY2025 full-year result was $301.2 million, up 10.03% from the prior year.
• Equity Average for Q1 2026 stood at $323.4 million, up from $269.8 million in the prior quarter.
• The five-year high for Equity Average was $383.0 million in Q2 2024, with the low at $213.2 million in Q4 2023.
• Historically, Equity Average has averaged $293.6 million across 5 years, with a median of $291.3 million in 2025.
• Annual changes were most pronounced in 2022 — Equity Average surged 2002.83% — and 2025, when it slipped 23.5%.
• Tyra Biosciences' Equity Average stood at $262.8 million in 2022, then dropped by 18.87% to $213.2 million in 2023, then surged by 65.43% to $352.7 million in 2024, then declined by 23.5% to $269.8 million in 2025, then grew by 19.84% to $323.4 million in 2026.
• The last three Equity Average figures came in at $323.4 million (Q1 2026), $269.8 million (Q4 2025), and $291.3 million (Q3 2025), per Business Quant data.